The most common side effects of tirzepatide are gastrointestinal — nausea (25-31%), diarrhea (19-23%), vomiting (8-12%), constipation (6-10%), and decreased appetite (9-11%). Most are transient and dose-related, decreasing as the body adjusts.
Side effect management strategies include: starting at 2.5 mg and following the standard titration schedule; eating smaller meals; staying hydrated; avoiding high-fat or high-sugar meals during titration; and discussing antiemetic medications with the prescriber if nausea is severe. Serious adverse events are rare but include pancreatitis, gallbladder disease, kidney injury (typically dehydration-related), and severe allergic reactions. Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies.
NexLife is structured around clinical best practices for tirzepatide. The same flat-rate pricing applies across the entire titration schedule ($186/mo on the 12-month plan from 2.5 mg through 15 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000